DOCSLIB.ORG

Computational Toxinology Joseph D. Romano Submitted in Partial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Computational Toxinology Joseph D. Romano Submitted in Partial Computational Toxinology Joseph D. Romano Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2019 Oc 2019 Joseph D. Romano All rights reserved ABSTRACT Computational Toxinology Joseph D. Romano Venoms are complex mixtures of biological macromolecules and other com- pounds that are used for predatory and defensive purposes by hundreds of thousands of known species worldwide. Throughout human history, venoms and venom components have been used to treat a vast array of illnesses, causing them to be of great clinical, economic, and academic interest to the drug dis- covery and toxinology communities. In spite of major computational advances that facilitate data-driven drug discovery, most therapeutic venom effects are still discovered via tedious trial-and-error, or simply by accident. In this dis- sertation, I describe a body of work that aims to establish a new subdiscipline of translational bioinformatics, which I name “computational toxinology”. To accomplish this goal, I present three integrated components that span a wide range of informatics techniques: (1) VenomKB, (2) VenomSeq, and (3) VenomKB’s Semantic API. To provide a platform for structuring, representing, retrieving, and integrating venom data relevant to drug discovery, VenomKB provides a database-backed web application and knowledge base for compu- tational toxinology. VenomKB is structured according to a fully-featured on- tology of venoms, and provides data aggregated from many popular web re- sources. VenomSeq is a biotechnology workflow that is designed to generate new high-throughput sequencing data for incorporation into VenomKB. Specif- ically, we expose human cells to controlled doses of crude venoms, conduct RNA-Sequencing, and build profiles of differential gene expression, which we then compare to publicly-available differential expression data for known dis- eases and drugs with known effects, and use those comparisons to hypothesize ways that the venoms could act in a therapeutic manner, as well. These data are then integrated into VenomKB, where they can be effectively retrieved and evaluated using existing data and known therapeutic associations. VenomKB’s Semantic API further develops this functionality by providing an intelligent, powerful, and user-friendly interface for querying the complex underlying data in VenomKB in a way that reflects the intuitive, human-understandable mean- ing of those data. The Semantic API is designed to cater to the needs of advanced users as well as laypersons and bench scientists without previous ex- pertise in computational biology and semantic data analysis. In each chapter of the dissertation, I describe how we evaluated these 3 components through various approaches. We demonstrate the utility of Ven- omKB and the Semantic API by testing a number of practical use-cases for each, designed to highlight their ability to rediscover existing knowledge as well as suggesting potential areas for future exploration. We use statistics and data science techniques to evaluate VenomSeq on 25 diverse species of venomous an- imals, and propose biologically feasible explanations for significant findings. In evaluating the Semantic API, I show how observations on VenomSeq data can be interpreted and placed into the context of past research by members of the larger toxinology community. Computational toxinology is a toolbox designed to be used by multiple stakeholders (toxinologists, computational biologists, and systems pharmacolo- gists, among others) to improve the return rate of clinically-significant findings from manual experimentation. It aims to achieve this goal by enabling access to data, providing means for easy validation of results, and suggesting specific hy- potheses that are preliminarily supported by rigorous inferential statistics. All components of the research I describe are open-access and publicly available, to improve reproducibility and encourage widespread adoption. Contents List of Figures iv List of Tables vi Acknowledgements vii Dedication ix 1. Background and Introduction1 1.1. Dissertation Overview . .3 1.1.1. Specific aims . .3 1.1.2. Knowledge gaps . .7 1.1.3. Significance and contributions . .9 1.1.4. Limitations . 11 1.2. Toxins, toxinology, and natural products . 13 1.3. Informatics methods in natural product drug discovery . 14 1.3.1. Classes of therapeutic natural products . 19 1.3.2. Cheminformatics methods . 24 1.3.3. Bioinformatics methods . 29 1.3.4. Semantic (knowledge-based) methods . 34 1.3.5. Gaps and opportunities in NP drug discovery . 43 1.3.6. Data needs for NP drug discovery . 45 1.4. Semantic knowledge resources . 47 1.4.1. Knowledge representations . 47 1.4.2. Constructing and using ontologies . 49 1.5. Data-driven discovery from gene expression data . 51 1.5.1. Data-driven science . 51 1.5.2. Differential expression analysis . 54 2. An informatics infrastructure for computational toxinology 58 2.1. VenomKB v1 . 58 2.1.1. Introduction . 58 2.1.2. Methods . 61 2.1.3. Description of data in VenomKB v1.0 . 65 2.1.4. Technical validation of VenomKB v1 . 69 i 2.1.5. VenomKB v1 usage notes . 73 2.1.6. VenomKB v1 Data Citations . 75 2.2. Venom Ontology . 75 2.2.1. Introduction . 75 2.2.2. Methods . 76 2.2.3. Results . 79 2.2.4. Discussion . 86 2.3. VenomKB v2 . 90 2.3.1. Results . 91 2.3.2. Discussion . 102 2.3.3. Methods . 106 3. A transcriptomic approach for generating therapeutic effect data from venoms 111 3.1. Introduction (VenomSeq)............................ 111 3.1.1. Enrichment analysis . 111 3.2. Results (VenomSeq)............................... 115 3.2.1. Venom dosages . 116 3.2.2. mRNA sequencing of venom-perturbed human cells . 118 3.2.3. Differential expression signatures of venom-perturbed human cells . 118 3.2.4. Associations between venoms and existing drugs . 119 3.2.5. Associations between venoms and disease regulatory networks . 130 3.3. Discussion (VenomSeq)............................. 131 3.3.1. Venoms versus small-molecule drugs . 131 3.3.2. Venoms versus human diseases . 132 3.3.3. Biologically plausible therapeutic hypotheses . 133 3.3.4. Accessing and querying VenomSeq data . 137 3.3.5. VenomSeq data analysis software . 138 3.3.6. Transitioning from venoms to venom components . 138 3.3.7. Applying VenomSeq to other natural product classes . 139 3.3.8. Interpreting connectivity analysis validation results . 140 3.4. Methods (VenomSeq).............................. 142 3.4.1. Reagents and materials . 142 3.4.2. Obtaining 25 venoms . 143 3.4.3. Growth inhibition assays . 143 3.4.4. mRNA Sequencing . 146 3.4.5. Constructing expression signatures . 147 3.4.6. Comparing venoms to known drugs and diseases . 147 3.4.7. Assessing sequencing technology and cell type compatibility . 153 ii 4. Integrating and delivering venom knowledge using semantic data analysis 155 4.1. Structuring and representing VenomSeq data in VenomKB . 155 4.2. The VenomKB Semantic API . 156 4.2.1. Related work and advantages over existing tools . 158 4.2.2. A theoretical framework for the semantic API . 160 4.2.3. Semantic API implementation . 162 4.2.4. The benefits of a semantic API . 169 4.2.5. Complete example . 171 4.2.6. Task-based evaluation of the semantic API for computational toxinol- ogy.................................... 174 4.2.7. Using the semantic API in other research contexts . 182 4.3. Automating discovery with VenomKB . 183 5. Conclusions 186 5.1. Summary of findings and original contributions . 186 5.2. Limitations and future work . 189 Bibliography 191 Appendix A. PLATE-Seq quality control data 217 Appendix B. VenomSeq JSON schema 222 Appendix C. Listing of algorithms 225 C.1. Connectivity analysis . 225 C.2. VIPER and aREA-3T . 226 C.3. The Semantic API . 228 Appendix D. Code availability 231 iii List of Figures 1.1. Therapeutic venom examples . .2 1.2. Graphical abstract . .4 1.3. XKCD webcomic—“How Standards Proliferate” . 12 1.4. Informatics methods in NP drug discovery . 15 1.5. Prot´eg´escreenshot . 50 1.6. Hypothesis-driven vs. data-driven science . 52 2.1. Schematic of VenomKB (v1.0) . 59 2.2. VenomKB v1 home page . 60 2.3. VenomKB v1 home page . 70 2.4. VO class diagram . 79 2.5. Venom sequence similarity networks . 81 2.6. Distributions of venom complexity in VO . 85 2.7. VenomKB v2 home page . 92 2.8. VenomKB v2 class diagram . 93 2.9. Datatype counts in VenomKB . 95 2.10. Venom complexity by taxonomic group . 96 2.11. VenomKB drug and target example . 98 2.12. List of data entries in VenomKB . 101 2.13. Interface for a data record in VenomKB . 110 3.1. VenomSeq graphical abstract . 112 3.2. GSEA example . 115 3.3. Venom growth inhibiton plots . 117 3.4. MA plot; O. macropus . 120 3.5. Connectivity analysis results . 121 3.6. Connectivity score density plots . 124 3.7. Validating VenomSeq technology with known drugs . 126 3.8. Digoxin and ATP1A . 135 3.9. FGFR signaling . 136 3.10. RNA-Seq workflow summary. 142 3.11. VenomSeq species cladogram . 145 3.12. Data analysis workflow summary . 148 4.1. Semantic API schematic; simplified view . 163 iv 4.2. Semantic API schematic; detailed view . ..
Load more

Recommended publications
  • Muraglitazar Bristol-Myers Squibb/Merck Daniella Barlocco
    Muraglitazar Bristol-Myers Squibb/Merck Daniella Barlocco Address Originator Bristol-Myers Squibb Co University of Milan . Istituto di Chimica Farmaceutica e Tossicologica Viale Abruzzi 42 Licensee Merck & Co Inc 20131 Milano . Italy Status Pre-registration Email: [email protected] . Indications Metabolic disorder, Non-insulin-dependent Current Opinion in Investigational Drugs 2005 6(4): diabetes © The Thomson Corporation ISSN 1472-4472 . Actions Antihyperlipidemic agent, Hypoglycemic agent, Bristol-Myers Squibb and Merck & Co are co-developing Insulin sensitizer, PPARα agonist, PPARγ agonist muraglitazar, a dual peroxisome proliferator-activated receptor-α/γ . agonist, for the potential treatment of type 2 diabetes and other Synonym BMS-298585 metabolic disorders. In November 2004, approval was anticipated as early as mid-2005. Registry No: 331741-94-7 Introduction [579218], [579221], [579457], [579459]. PPARγ is expressed in Type 2 diabetes is a complex metabolic disorder that is adipose tissue, lower intestine and cells involved in characterized by hyperglycemia, insulin resistance and immunity. Activation of PPARγ regulates glucose and lipid defects in insulin secretion. The disease is associated with homeostasis, and triggers insulin sensitization [579216], older age, obesity, a family history of diabetes and physical [579218], [579458], [579461]. PPARδ is expressed inactivity. The prevalence of type 2 diabetes is increasing ubiquitously and has been found to be effective in rapidly, and the World Health Organization warns that, controlling dyslipidemia and cardiovascular diseases unless appropriate action is taken, the number of sufferers [579216]. PPARα agonists are used as potent hypolipidemic will double to over 350 million individuals by the year compounds, increasing plasma high-density lipoprotein 2030. Worryingly, it is estimated that only half of sufferers (HDL)-cholesterol and reducing free fatty acids, are diagnosed with the condition [www.who.int].
    [Show full text]
  • 7-Azaindoles and Their Use As Ppar Agonists 7-Azaindole Und Ihre Verwendung Als Ppar-Agonisten 7-Azaindoles Et Leur Utilisation Comme Agonistes De Ppar
    (19) TZZ___T (11) EP 1 794 159 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 471/04 (2006.01) A61K 31/437 (2006.01) 01.08.2012 Bulletin 2012/31 A61P 3/10 (2006.01) (21) Application number: 05778246.8 (86) International application number: PCT/EP2005/009269 (22) Date of filing: 27.08.2005 (87) International publication number: WO 2006/029699 (23.03.2006 Gazette 2006/12) (54) 7-AZAINDOLES AND THEIR USE AS PPAR AGONISTS 7-AZAINDOLE UND IHRE VERWENDUNG ALS PPAR-AGONISTEN 7-AZAINDOLES ET LEUR UTILISATION COMME AGONISTES DE PPAR (84) Designated Contracting States: • GLIEN, Maike AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 65195 Wiesbaden (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • SCHAEFER, Hans-Ludwig SK TR 65239 Hochheim (DE) • WENDLER, Wolfgang (30) Priority: 11.09.2004 EP 04021667 65618 Selters (DE) • BERNARDELLI, Patrick (43) Date of publication of application: F-78450 Villepreux (FR) 13.06.2007 Bulletin 2007/24 • TERRIER, Corinne F-93190 Livry Gargan (FR) (73) Proprietor: Sanofi-Aventis Deutschland GmbH • RONAN, Baptiste 65929 Frankfurt am Main (DE) F-92140 Clamart (FR) (72) Inventors: (56) References cited: • KEIL, Stefanie EP-A- 1 445 258 WO-A-2004/074284 65719 Hofheim (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • The Leading Source of Diabetes Business News the Long View Fall
    The Leading Source of Diabetes Business News The Long View Fall 2011 • No. 108 Although change isn’t literally in the air for me – here in San Francisco, we still get a few more weeks of summer – autumn brings some notable shifts in the world of diabetes, and I’m looking forward to hearing all about them in companies’ third-quarter financial updates. Perhaps most importantly, Amylin/Lilly/Alkermes’ Bydureon, the first once-weekly diabetes therapy, has now made its debut in several European countries. That means this earnings’ season will be the first chance to hear how the launch has gone, and we’ll get our first real indicator of what to expect in the quarters to come. Will patients flock to the every-seven-days dosage schedule, forcing rival GLP-1 companies to accelerate development of their own once-weekly products (and encouraging Amylin/Lilly/Alkermes to stay on course with their phase 2 once-monthly exenatide)? Or will factors like needle size, injection simplicity – and even the regularity of daily dosing, considered an advantage by some – give the edge to Victoza? (Novo Nordisk certainly isn’t resting on the success of this soon-to- be-blockbuster, having most recently launched Victoza in the swiftly growing Chinese market – a topic we explore in this issue’s interview with Novo Nordisk’s head of China, Ron Christie.) The global GLP-1 contest was already intensely competitive and has become more so, even before Bydureon’s entry to the US or the arrival of new players (e.g., Sanofi’s Lyxumia).
    [Show full text]
  • S 26948: a New Specific Peroxisome Proliferator–Activated Receptor
    ORIGINAL ARTICLE S 26948: a New Specific Peroxisome Proliferator–Activated Receptor ␥ Modulator With Potent Antidiabetes and Antiatherogenic Effects Maria Carmen Carmona,1 Katie Louche,1 Bruno Lefebvre,2 Antoine Pilon,3 Nathalie Hennuyer,3 Ve´ronique Audinot-Bouchez,4 Catherine Fievet,3 Ge´rard Torpier,3 Pierre Formstecher,2 Pierre Renard,5 Philippe Lefebvre,2 Catherine Dacquet,5 Bart Staels,3 Louis Casteilla,1 and Luc Pe´nicaud1 on behalf of the Consortium of the French Ministry of Research and Technology OBJECTIVE—Rosiglitazone displays powerful antidiabetes benefits but is associated with increased body weight and adipo- genesis. Keeping in mind the concept of selective peroxisome he peroxisome proliferator–activated receptors proliferator–activated receptor (PPAR)␥ modulator, the aim of this (PPARs) (1) are transcription factors belonging study was to characterize the properties of a new PPAR␥ ligand, S to the nuclear receptor transcription factor fam- 26948, with special attention in body-weight gain. Tily (1). Three isoforms, PPAR␣,-␦, and -␥, have RESEARCH DESIGN AND METHODS—We used transient been described to have tissue-specific patterns of expres- transfection and binding assays to characterized the binding sion and function—the latter being highly expressed in characteristics of S 26948 and GST pull-down experiments to adipocytes and macrophages among other cell types (2–5). investigate its pattern of coactivator recruitment compared with The role of PPAR␥ on adipocyte differentiation has been rosiglitazone. We also assessed its adipogenic capacity in vitro extensively studied in vitro and in vivo (2,3,6,7). Forced using the 3T3-F442A cell line and its in vivo effects in ob/ob mice ␥ (for antidiabetes and antiobesity properties), as well as the expression of PPAR in nonadipogenic cells is sufficient to homozygous human apolipoprotein E2 knockin mice (E2-KI) (for induce adipocyte differentiation on treatment with specific antiatherogenic capacity).
    [Show full text]
  • Role of Dual PPAR Gamma and Alpha Agonists in Diabetes Mellitus
    23 Role of Dual PPAR γ and α Agonists in Diabetes Mellitus—Have They Met a Road Block or They Are Dead? Mohd Ashraf Ganie, Abdul Hamid Zargar Abstract: There are three peroxisome proliferator-activated receptors (PPARs) subtypes which are commonly designated PPAR alpha, PPAR gamma and PPAR beta/delta. PPAR alpha activation increases high density lipoprotein (HDL) cholesterol synthesis, stimulates “reverse” cholesterol transport and reduces triglycerides. PPAR gamma activation results in insulin sensitization and antidiabetic action. Combined treatments with PPAR gamma and alpha agonists may potentially improve insulin resistance and alleviate atherogenic dyslipidemia, whereas PPAR delta properties may prevent the development of overweight which typically accompanies “pure” PPAR gamma ligands. The new generation of dual-action PPARs—the glitazars, which target PPAR-gamma and PPAR-alpha (like muraglitazar and tesaglitazar) were on deck in late-stage clinical trials for sometime and were considered effective in reducing cardiovascular risk, but their long-term clinical effects were unknown. Thus glitazars offered a hope of a new approach to diabetes care addressing not just glycemia, but dyslipidemia and other components of the metabolic syndrome, though the side effect profile remains unknown. No human data is available, and so it remains highly speculative. The glitazars and on the newly published results for muraglitazar and tesaglitazar. “The PPAR-alpha is a good target and is being developed to yield more potent drugs that work through PPAR-alpha, and at the same time, improve on the PPAR-gamma. Efforts is on to get the glucose lowering with few of the adverse effects. This thinking has met with problems as many clinical trials have been terminated due to dominant side effects.
    [Show full text]
  • George Grunberger, M.D., F.A.C.P., F.A.C.E
    GEORGE GRUNBERGER, M.D., F.A.C.P., F.A.C.E. Chairman, Grunberger Diabetes Institute Clinical Professor, Department of Internal Medicine Clinical Professor, Center for Molecular Medicine & Genetics Wayne State University School of Medicine Professor, Department of Internal Medicine Oakland University William Beaumont School of Medicine Visiting Professor, First Faculty of Medicine Charles University, Prague (Czech Republic) Phone: (248) 335-7740 43494 Woodward Ave, ste 208, Bloomfield Hills, MI 48302 Fax: (248) 338-7979 e-mail: [email protected] EDUCATION 1973 BA degree (Biochemistry), Columbia College, New York, NY 1977 MD degree, New York University School of Medicine, New York, NY TRAINING 1977-1980 Residency, Internal Medicine Case Western Reserve University University Hospitals of Cleveland, Cleveland, Ohio 1980-1983 Fellowship (clinical and basic research), Endocrinology and Metabolism, Diabetes Branch, National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases National Institutes of Health, Bethesda, Maryland FACULTY APPOINTMENTS, Wayne State University, Detroit, Michigan 1986-1992 Associate Professor (tenured), Department of Internal Medicine Associate Professor (tenured), Department of Molecular Biology and Genetics 1992-2002 Professor (tenured), Department of Internal Medicine 1995-1996 Interim Chairman, Department of Internal Medicine 1992-1994 Professor (tenured), Department of Molecular Biology & Genetics 1994-present Professor (tenured), Center for Molecular Medicine & Genetics 1986-present Regular member
    [Show full text]
  • Oral Hypoglycemic Drugs in the Management of Type 2 Diabetes Mellitus: a Review
    Journal of Health, Medicine and Nursing www.iiste.org ISSN 2422-8419 An International Peer-reviewed Journal Vol.44, 2017 Oral Hypoglycemic Drugs in the Management of Type 2 Diabetes Mellitus: A Review Nikesh Mani Shrestha 1* Bang Zhu Meng 2 1.School of Clinical Medicine, Inner Mongolia University for the Nationalities,536 West Huo Lin He Street, Horqin District, Tongliao City, Inner Mongolia, China 2.Affiliated Hospital of Inner Mongolia University for the Nationalities, 1742 Huo Lin He Street, Horqin District, Tongliao City, Inner Mongolia, China Abstract Diabetes mellitus is a chronic, progressive, heterogeneous group of metabolic disorder mainly characterized by hyperglycemia. T2DM results due to insulin resistance or secretory defects of a beta cell or both and gradually progress to a state characterized by complete loss of pancreatic beta cells secretion. 2hour oral glucose tolerance test or HbA1c testing is performed for the screening for diabetes mellitus. In this review, we attempt to outline the basic pharmacological and non-pharmacological principles for the management of T2DM. Keywords: diabetes, clinical management, non-pharmacological management, primary care 1. Introduction Diabetes mellitus is one of the common chronic metabolic diseases which is mainly characterized by hyperglycemia. It is a progressive disease. So, as a disease progresses there is a high chance of developing microvascular and macrovascular complications. Many studies have been conducted to find the effective measure to reduce these complications. Based on the pathology, there are different types of diabetes mellitus. Among them, type 2 diabetes (T2D) is very common accounting for approximately 90% of diabetic cases worldwide. The prevalence rate of T2DM is increasing due to a sedentary lifestyle, increasing obesity and an aging population (Johnson JA et al, 2006).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,533,022 B2 Mehta Et Al
    USO09533022B2 (12) United States Patent (10) Patent No.: US 9,533,022 B2 Mehta et al. (45) Date of Patent: *Jan. 3, 2017 (54) PEPTIDE ANALOGS FOR TREATING (56) References Cited DISEASES AND DISORDERS U.S. PATENT DOCUMENTS (71) Applicants: Nozer M. Mehta, Randolph, NJ (US); 4,764,589 A 8, 1988 Orlowski William Stern, Tenafly, NJ (US); Amy 9,006,172 B2 * 4/2015 Mehta .................... A61K 38.23 M. Sturmer, Towaco, NJ (US); Morten 514/1.1 Asser Karsdal, Kobenhavn (DK); Kim 2002/0065255 A1* 5/2002 Bay .................. A61K 47, 183 Henriksen, Hillerod (DK) 514,166 2010/0311650 A1* 12/2010 Mehta .................... CO7K 1400 (72) Inventors: Nozer M. Mehta, Randolph, NJ (US); 514,49 William Stern, Tenafly, NJ (US); Amy M. Sturmer, Towaco, NJ (US); Morten FOREIGN PATENT DOCUMENTS Asser Karsdal, Kobenhavn (DK); Kim Henriksen, Hillerod (DK) WO 2010O85700 A2 T 2010 (73) Assignee: KeyBioscience A/S, Stans (CH) OTHER PUBLICATIONS Lee et al., “Metformin Decreases Food Consumption and Induces (*) Notice: Subject to any disclaimer, the term of this Weight Loss in Subjects with Obesity with Type Il Non-Insulin patent is extended or adjusted under 35 Dependent Diabetes,” Obes. Res. 6:47-53 (1998).* U.S.C. 154(b) by 0 days. Feigh et al., “A novel oral form of Salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese This patent is Subject to a terminal dis rats' Diab. Obesity Metab. 13:911-920 (2011).* claimer. Unigene Laboratories Inc. Unigene Laboratories Inc. Corporate Overview 2010, URL: www.getfillings.com/sec-filings/100325/ (21) Appl.
    [Show full text]
  • 09.Subjectindex ADA 13.Indd
    SUBJECT INDEX (-)-Epigallocatechin-3-gallate 2919-PO Add-on to basal insulin 1102-P Aggressiveness factor 2526-PO 1,5-Anhydroglucitol 928-P Add-on to metformin 1092-P Aging 1284-P, 1396-P, 1399-P, 1797-P, 1966-P, 11 β-HSD 1993-P Add-on to metformin + SU 1082-P 1972-P, 1981-P, 2007-P, 2209-P, 2308-PO, 11beta-HSD, glucocorticosteroids, type 2 diabetes Add-on to pioglitazone 1120-P 2481-PO, 2693-PO, 2697-PO 1128-P Adenine nucleotide translocase 28-OR, 29-OR Aging society 2657-PO 11β-HSD1 1875-P Adenosine A1 receptor 1854-P Agreement 2508-PO SUBJECT INDEX 12(S)-HETE 2057-P Adenovirus, shrna, over expression 340-OR Agrp neurons 1917-P 12/15-Lipoxygenase 2057-P Adherence 652-P, 789-P, 802-P, 814-P, 821-P, 857-P, AICAR 1815-P 12-Lipoxygenase 338-OR 889-P, 894-P, 1227-P, 1259-P, 1423-P, 2504-PO Akita 1643-P 14-3-3 142-OR Adhesive capsulitis 2887-PO Akt 25-OR 18FDG PET 2026-P Adipocyte 100-OR, 1644-P, 1748-P, 1748-P, 1749-P, Akt mediated signaling pathway 2321-PO 18F-TTCO-cys40-exendin-4 2163-P 1751-P, 1752-P, 1755-P, 1756-P, 1758-P, 1761-P, Akt, glucose uptake 1802-P 1-h plasma glucose 1457-P, 2808-PO 1763-P, 1765-P, 1769-P, 1769-P, 2056-P, 2943-PO Akt/GSK3 signaling pathway 488-P 25(OH)D 679-P Adipocyte differentiation 144-OR, 1745-P, 1745-P, Akt2 1818-P 25-hydroxivitamin D 2035-P 2013-P Alanine 1916-P 26S Proteasomes 498-P Adipocyte fatty acid-binding protein 2003-P Alanine aminotransferase 1460-P, 2860-PO 2-Aminobicyclo-(2,2,1)-heptane-2-carboxylic acid Adipocyte precursor cells 2081-P Alaska native people 183-OR 2079-P Adipocytes 94-OR, 95-OR,
    [Show full text]
  • Toxicological Profile for Wood Creosote, Coal Tar Creosote, Coal Tar, Coal Tar Pitch, and Coal Tar Pitch Volatiles
    TOXICOLOGICAL PROFILE FOR WOOD CREOSOTE, COAL TAR CREOSOTE, COAL TAR, COAL TAR PITCH, AND COAL TAR PITCH VOLATILES U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry September 2002 CREOSOTE ii DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. CREOSOTE iii UPDATE STATEMENT Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at: Agency for Toxic Substances and Disease Registry Division of Toxicology/Toxicology Information Branch 1600 Clifton Road NE, E-29 Atlanta, Georgia 30333 V FOREWORD This toxicological profile is prepared in accordance with guidelines" developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary. The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced. The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties.
    [Show full text]
  • 1 CURRICULUM VITAE George Stephen Decherney, MD, MPH Born
    CURRICULUM VITAE George Stephen DeCherney, MD, MPH Born: 16 June 1952 Wilmington, Delaware Education: 1970 Wilmington Friends School Wilmington, Delaware 1974 Columbia University New York, New York BA (Molecular Biology) 1978 Temple University School of Medicine Philadelphia, Pennsylvania MD 1994 University of Delaware Newark, Delaware Total Quality Management (certificate) 1998 Columbia University New York, New York M.P.H (Health Services Management) Military Service: 1986-89 Major, Medical Corps United States Air Force (Active Duty) 1989-1995 Major, Medical Corps United States Air Force (Reserves) Medical License: State of Pennsylvania License # MD-022537-E North Carolina 01722 1 Professional Career (current): 2011- Board of Directors, Theorem Clinical Research, King of Prussia, PA 2009- Clinical Professor of Medicine, Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine 2009- Senior Advisor, London Genetics Company, London, England 2008- Trustee, William Harvey Research Institute, of Queen Mary Medical College, St Barts and the London Hospitals, London, England 2008- Senior Global Advisor, London School of Hygiene and Tropical Medicine, University of London 2008-2010 Board of Directors, Symyx Corporation, Santa Clara, California Member, Audit committee 2007-2008 Chief Innovation Officer, Quintiles Transnational Corporation Research Triangle Park, North Carolina 2004-2007 President, Global Clinical Research Organization Quintiles Transnational Corporation Research Triangle Park, North Carolina
    [Show full text]
  • (PPAR) Agonists Activate Hepatitis B Virus Replication in Vivo Lingyao Du, Yuanji Ma, Miao Liu, Libo Yan and Hong Tang*
    Du et al. Virology Journal (2017) 14:96 DOI 10.1186/s12985-017-0765-x RESEARCH Open Access Peroxisome Proliferators Activated Receptor (PPAR) agonists activate hepatitis B virus replication in vivo Lingyao Du, Yuanji Ma, Miao Liu, Libo Yan and Hong Tang* Abstract Background: PPAR agonists are often used in HBV infected patients with metabolic disorders. However, as liver- enriched transcriptional factors, PPARs would activate HBV replication. Risks exsit in such patients. This study aimed to assess the influence of commonly used synthetic PPAR agonists on hepatitis B virus (HBV) transcription, replication and expression through HBV replicative mouse models, providing information for physicians to make necessary monitoring and therapeutic adjustment when HBV infected patients receive PPAR agonists treatment. Methods: The HBV replicative mouse model was established by hydrodynamic injection of HBV replicative plasmid and the mice were divided into four groups and treated daily for 3 days with saline, PPAR pan-agonist (bezafibrate), PPARα agonist (fenofibrate) and PPARγ agonist (rosiglitazone) respectively. Their serum samples were collected for ECLIA analysis of HBsAg and HBeAg and real-time PCR analysis of Serum HBV DNA. The liver samples were collected for DNA (Southern) filter hybridization of HBV replication intermediates, real-time PCR analysis of HBV mRNA and immunohistochemistry (IHC) analysis of hepatic HBcAg. The alternation of viral transcription, replication and expression were compared in these groups. Result: Serum HBsAg, HBeAg and HBV DNA were significantly elevated after PPAR agonist treatment. So did the viral replication intermediates in mouse livers. HBV mRNA was also significantly increased by these PPAR agonists, implying that PPAR agonists activate HBV replication at transcription level.
    [Show full text]